DSM-Firmenich, CH1216478797

DSM-Firmenich stock steadies as buyback reaches 5.58 million shares

Published on 08/25/2026 at 11:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock is supported by a weekly repurchase update dated August 25, 2026, after 225,858 shares were bought in the latest week at an average of €88.45.

Bauhaus-Poster mit geometrischen Formen, Molekül und Schriftzug SCIENCE
dsm-firmenich AG (ISIN CH1216478797) erscheint als geometrisches Bauhaus-Poster mit Molekülformen und dem Wort SCIENCE, Illustration mit AI erstellt.

DSM-Firmenich stock is backed by a new buyback update dated August 25, 2026: the group repurchased 225,858 shares between August 17 and August 21 at an average price of €88.45, for a total of €20.0 million.

The company said the program has now reached 5,578,038 shares repurchased at an average price of €69.93, equal to €390.1 million in total consideration, and the capital-reduction program is intended to run through the end of Q3 2026.

Repurchase pace stays visible

The latest weekly tranche is smaller than the program total, but the cumulative figure shows how much capital has already been returned since the program started on March 12, 2026. On the company’s own release, the wider initiative was announced on February 9, 2026 with an aggregate market value of €500 million for capital reduction and €40 million for share-plan coverage.

That makes the current pace easy to measure: 225,858 shares in one week against 5,578,038 shares in total to date. For investors, the split between the €40 million share-plan tranche and the €500 million reduction program remains the key framing device.

Trading stays firm

On a market-data page for DSM-Firmenich, the shares were quoted at €90.23 on August 24, 2026, with a 5-day move of 0.00 percent and a year-to-date gain of 31.38 percent.

The same page lists the company under ISIN CH1216478797 and shows the stock at the CBOE reference level used on the page. The combination of a €90.23 quote and a 31.38 percent year-to-date move gives the buyback another market backdrop to be read against.

Product angle

PARSOL Shield is one of the company’s recent consumer-facing ingredients, and the release history on the company’s investor pages shows FDA approval for the sun-protection ingredient on June 10, 2026. That adds a second current thread beside capital returns: a nutrition, health, and beauty group still using product development alongside shareholder distributions.

Price and listing

The stock closed at €90.23 on August 24, 2026 on the quoted market-data page, while the repurchase update was published on August 25, 2026. DSM-Firmenich remains listed on Euronext Amsterdam and SIX Swiss Exchange.

Company

Company: DSM-Firmenich AG
ISIN: CH1216478797
Ticker: 0AC9
Exchange: Euronext Amsterdam and SIX Swiss Exchange
Price (as of August 24, 2026, 5:30 p.m. ET): €90.23
Market cap: €25.5 billion
Sector / Industry: Consumer staples / Specialized consumer goods
Index membership: STOXX Europe 600

Read more

More on DSM-Firmenich stock

Disclaimer...

en | CH1216478797 | DSM-FIRMENICH | boerse | 69998319 | bgmi